| Low-dose Interferon-alfa Does Not Improve Outcomes of Patients with Renal Cell ... - Cancer Consultants |
|
|
Cancer ConsultantsUpfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and ... read more |